-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IEOkkaIKp8BQeVBFxv3f8kj5HLHAtTBtNyYpVQMBF4yQ8aelTMjBBFrIkMgDJCMn 6Zv4TIYQxxn34Gkdul8DCw== 0000950134-02-010084.txt : 20020814 0000950134-02-010084.hdr.sgml : 20020814 20020814160937 ACCESSION NUMBER: 0000950134-02-010084 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020814 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: FILED AS OF DATE: 20020814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 02736643 BUSINESS ADDRESS: STREET 1: 425 WOODSMILL RD CITY: ST LOUIS STATE: MO ZIP: 63017 BUSINESS PHONE: 3145799899 MAIL ADDRESS: STREET 1: 425 WOODSMILL RD CITY: ST LOUIS STATE: MO ZIP: 63017 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 19940606 8-K 1 c71278e8vk.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2002 ---------------------- COMMISSION FILE NUMBER 1-12584 DELAWARE SHEFFIELD PHARMACEUTICALS, INC. 13-3808303 (State of other jurisdiction of (Exact name of registrant as specified (I.R.S. Employer incorporation or organization) in its charter) Identification No.)
14528 South Outer Forty Road, Suite 205, St. Louis, Missouri 63017 - -------------------------------------------------------------------------------- (Address of principal executive officers) (Zip Code) Registrant's telephone number, including area code (314) 579-9899 ---------------------- Not Applicable -------------------------------------------------------------- (Former name or former address, if changed since last report) ITEM 9. REGULATION FD DISCLOSURE Sheffield Pharmaceuticals, Inc. (the "Company"), a Delaware corporation, is furnishing under Item 9 of this Current Report on Form 8-K the information included as Exhibit 99.1 to this report. Exhibit 99.1 includes a certification signed by the Company's Chief Executive Officer and Chief Financial Officer as required pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in connection with the Quarterly Report on Form 10-Q for the period ending June 30, 2002. Note: The information in this report (including Exhibit 99.1) is furnished under Item 9 pursuant to 18 U.S.C. Section 1350 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits
Exhibit Number Description 99.1 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: August 14, 2002 By: /s/ Thomas M. Fitzgerald -------------------------------------- Thomas M. Fitzgerald President and Chief Executive Officer By: /s/ Scott A. Hoffmann -------------------------------------- Scott A. Hoffmann Vice President and Chief Financial Officer EX-99.1 3 c71278exv99w1.txt CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 EXHIBIT 99.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Sheffield Pharmaceuticals, Inc. (the Company") on Form 10-Q for the period ending June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on their knowledge: 1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and 2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in the Report. /s/ Thomas M. Fitzgerald - --------------------------------------------- Thomas M. Fitzgerald, Chief Executive Officer /s/ Scott A. Hoffmann - --------------------------------------------- Scott A. Hoffmann, Chief Financial Officer August 14, 2002 -----END PRIVACY-ENHANCED MESSAGE-----